Pancreatic Cancer Research

ResearcherOregon Health & Science UniversityActive in the last 2 years

Motoyuki Tsuda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2873-1449; OpenAlex author ID A5016513561, A5040991998. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
65
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: 6 papers · 2026: 3 papers

Papers 17

  1. Clonal heterogeneity in human pancreatic ductal adenocarcinoma and its impact on tumor progression. Co-author DOI 10.1038/s41588-026-02779-5↗
  2. Corrigendum to Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Co-author DOI 10.1172/jci206371↗
  3. Epigenetic progression of pancreatic cancer to aggressive subtypes involves alternate routes of lineage reprogramming in subtype-intermediate progenitor cells Co-author DOI 10.64898/2026.09.28.754674↗
  4. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Co-author DOI 10.1038/s43018-024-00881-3↗
  5. Self-amplifying NRF2-EZH2 epigenetic loop converts KRAS-initiated progenitors to invasive pancreatic cancer. Co-author DOI 10.1038/s43018-025-01003-3↗
  6. Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model Co-author DOI 10.1101/2025.07.14.664767↗
  7. The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3437↗
  8. Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Co-author DOI 10.1172/jci177533↗
  9. A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway Co-author DOI 10.64898/2025.12.12.693851↗
  10. Brg1 controls stemness and metastasis of pancreatic cancer through regulating hypoxia pathway. First author DOI 10.1038/s41388-023-02716-4↗
  11. Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment. Co-author DOI 10.3390/pharmaceutics15122651↗
  12. The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.14768↗
  13. Correction: CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-21-1255↗
  14. Visualization of stem cell activity in pancreatic cancer expansion by direct lineage tracing with live imaging. Co-author DOI 10.7554/elife.55117↗
  15. CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2745↗
  16. Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice. Co-author DOI 10.1136/gutjnl-2017-315425↗
  17. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice. Co-author DOI 10.1053/j.gastro.2018.03.039↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rosalie C. Sears · 8 shared papers, 2023–2026 · strength 1.40
  2. Hiroshi Seno · 9 shared papers, 2018–2026 · strength 1.13
  3. Takahisa Maruno · 8 shared papers, 2018–2026 · strength 0.96
  4. Akihisa Fukuda · 7 shared papers, 2018–2026 · strength 0.95
  5. Ellen M. Langer · 5 shared papers, 2023–2026 · strength 0.89
  6. Osamu Araki · 5 shared papers, 2018–2026 · strength 0.76
  7. Kevin Hawthorne · 4 shared papers, 2025–2026 · strength 0.74
  8. Patrick Joseph Worth · 4 shared papers, 2025–2026 · strength 0.74
  9. Jason M. Link · 4 shared papers, 2025–2026 · strength 0.73
  10. Brett C. Sheppard · 4 shared papers, 2023–2026 · strength 0.72
  11. Isabel A. English · 4 shared papers, 2025 · strength 0.65
  12. Dieter Saur · 4 shared papers, 2021–2026 · strength 0.64
  13. Jonathan Robert Brody · 4 shared papers, 2023–2025 · strength 0.63
  14. Vidhi M. Shah · 4 shared papers, 2023–2025 · strength 0.62
  15. Munenori Kawai · 3 shared papers, 2021–2026 · strength 0.57
  16. Toshihiko Masui · 3 shared papers, 2023–2026 · strength 0.53
  17. Makoto Sono · 3 shared papers, 2023–2026 · strength 0.53
  18. Etsuro Hatano · 3 shared papers, 2023–2026 · strength 0.53
  19. Terry K. Morgan · 3 shared papers, 2025 · strength 0.49
  20. Lisa M. Coussens · 3 shared papers, 2025 · strength 0.49
  21. Satoshi Ogawa · 4 shared papers, 2018–2026 · strength 0.46
  22. Tsutomu Chiba · 5 shared papers, 2018–2021 · strength 0.43
  23. Ethan S. Agritelley · 2 shared papers, 2025–2026 · strength 0.40
  24. Kei Iimori · 2 shared papers, 2025–2026 · strength 0.39
  25. Katherine R. Pelz · 2 shared papers, 2025 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.